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1. Introduction 
One of the major problems in neonatal care, is the presence of sleep apnea in premature 
infants. This is due, that respiratory disturbances placed at high-risk and in immediate 
danger to newborn infants because alteration in adaptation to extra-uterine environment. 
Apnea during sleep can be the principal symptom of maturational dysfunction of the 
control of the central nervous system (CNS) on the infant respiratory patterns, or can be 
present secondarily to other brain or non-brain pathologies. Frequency of apnea is inversely 
related to gestational age at birth. In this chapter, we revisited the process of sleep 
development from fetal to neonatal age focused in the presentation of respiratory 
alterations, such as the apnea. Afterward, we reviewed the clinical features of apnea for its 
clinical diagnosis and therapeutics. 
2. Development of sleep 
Different neuronal networks underlying brain function maturing during fetal life beginning 
as early as 10 weeks of gestational age (GA). For example, the human fetus displays 
spontaneous movements that can be visualized by means of ultrasonography (USG), which 
can document eye-opening and –closure, and rhythmic body movements. On the other 
hand, fetal heart rate can be electronically recorded by means of serial electrodes placed in 
the abdominal skin of the mother, fetal heart rate variations reveals the fetal well-being. 
Both tests, allow estimation of fetal state transitions underlying fetal behavior including the 
sleep. Recently, Magnetoencephalographic (MEG) recordings of the fetal and neonatal 
cortical magnetic activity constituted as a promising technique in the study of sleep 
physiology. At earlier stage of development, no clear sleep state can be well defined. The 
sleep stages appears clearly at the end of fetal period near at the time of birth.1 One study 
carried out in our laboratory suggested a high correlation of fetal sleep with those sleep 
measurements developed after birth in neonates.2 
After birth serial recording of several physiologic functions during sleep or polysomnography 
(PSG) can be obtained by continuous monitoring of electroencephalographic (EEG) signal; eye 
movements (EOG); electromyographic (EMG) signal of axial and limb muscles; 
electrocardiographic (EKG) recording; different measurements of respiratory function,  
such as those obtained by a nasal thermistor, chest and abdominal movements; blood 
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concentrations of oxygen and carbon dioxide sensors are placed in neonates in order to 
study the organization of the functional state.3 
Preterm infants born at 24 weeks of gestational age (GA) show predominant cyclic 
rudimentary sleep functional state called Transitional or Indeterminate sleep (IS). Scarce 
burst of electro-cortical activity over a flat background in EEG are presents which is called 
Discontinuous activity or Tracé Discontinu.4 When time intervals are measured between 
successive epochs of PSG signal, EEG activity shows variable Discontinuous activity 
depending on GA with larger flat EEG periods at earlier GA. By 34 weeks of conceptional 
age (CA = GA + post-natal legal age in weeks. Is the better parameter to measure and 
correct maturational effects of preterm birth and early post-natal life on the EEG and PSG 
recordings when are compared with those of newborns born at-term and with some weeks 
of post-natal age) a Rapid eye movements (REM) sleep-like state emerges, and is called 
Active sleep (AS). Around 37 weeks of CA Quiet sleep (QS) differentiates and appear as 
alternating intervals of variable span according to CA changes of different EEG frequency 
and amplitude patterns called Tracé Alternat, while in AS periods appears with continuous 
EEG activity or Tracé Continu. Cycle times vary between sleep periods, but usually range 
between 40 and 60 min. Behavioral estimations of IS approximate amounts 95% of sleep in 
the 30 weeks of CA studies, decreasing progressively and disappearing by near-term ages.5 
There is a relative continuity of sleep state from intrauterine through neonatal age, from last 
weeks of pregnancy to 44 weeks of CA. Such physiologic continuity may reflect the need for 
sleep state homeostasis of both the fetus and newborn during the transition from 
intrauterine to extra-uterine environments,2 requiring approximately one postnatal month of 
brain development before infant sleep patterns emerge. These physiologic interrelationships 
defining neonatal state, persist to 4–6 weeks of postnatal life after which infant sleep 
patterns subsequently emerge to eventually resemble those of adult sleep rhythms by 
between the first and second years of life. Similar temporal relationships are expressed by 
preterm neonates in an extra-uterine environment. However, a review of medical literature 
regarding fetal wakefulness suggests no convincing evidence that the fetus is awake as often 
as the preterm neonate. A state of cortical arousal similar to IS inhibits the awake state in the 
fetus as a defense response of brain plasticity.6  
3. Development of sleep respiratory patterns 
The recognition of sleep states in newborns and infants was initially based on differences in 
respiratory rate. The breathing rhythm was more irregular during AS and IS and more regular 
during QS segments. Related changes in these respiratory patterns first were noted when sleep 
state differentiation was recognized.7 There are a number of features of respiratory patterns 
that will be briefly summarized, including central respiratory pauses, breathing regularity 
versus irregularity, breathing frequency, and the percentage of paradoxical breathing as it 
refers to out-of-phase thoracic and abdominal breathing movements. Central respiratory 
pauses are of short duration and are normally seen in the newborn and can be documented 
also during the waking state following body movements. However, they primarily occur 
during sleep.8 The apnea index, defined by the percentage of non-breathing time,9 is 
significantly higher during AS than QS. It remains high until 38 weeks of CA and decreases 
significantly both during AS and QS by term age. Preterm infants corrected to term age as well 
as gestational-age infants who are small for their age also have a greater number of respiratory 
pauses than is appropriate for gestational-age infants of the same CA. 
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After 35 weeks of CA, respiratory frequency is higher during AS and QS. During both 
components of the sleep cycle, respiratory frequency increases with increasing gestational 
age to term and continues to increase during the first two months of life. Thereafter, at older 
ages, the respiratory rate progressively decreases. Phase shifting or paradoxical breathing 
between thoracic and abdominal breathing movements is commonly seen during the first 
several months of life and is closely related to inter-costal muscle inhibition, particularly 
during active sleep, in part reflecting high chest wall compliance. By the at-term age of 
pregnancy, the time spent with 180o out-of-phase shift between thoracic and abdominal 
breathing movements remains unchanged but is significantly greater during AS than QS.10  
4. Definition and different types of apnea 
Apnea in newborns is defined as absence of breathing for 20 sec or longer, or at a shorter time 
if bradycardia of <100 beats/min, cyanosis, hypoxia, and/or hypotension is present.11 Apnea 
is classified as central, obstructive, and mixed. Central apnea is present when epochs of 
absence of nasal air flow and thoracic breathing are identified, obstructive apnea is recognized 
when respiratory thoracic movements are present but nasal air flow is inadequate, and mixed 
type is present when events begin or end with central or obstructive apnea and change to the 
other type of apnea.12 PSG is the most adequate electrophysiologic test to identify apnea in 
preterm and at-term newborns, and must be performed in all infants with risk factors. 
5. Risk factors for different types apnea 
We carried-out a study at a tertiary-level medical center for care of high-risk newborns at 
Neonatal Intensive Care Unit in Mexico City. Newborns were selected if they presented any 
risk factor for apnea during neonatal period (such as preterm birth, low Apgar score, sepsis, 
and others) when infants were stable and not mechanically ventilated. The sample was 
divided in infants that presented and those that did not presented apnea events on PSG 
studies. Newborns were studied by a neurologic examination, transfontanelar 
ultrasonography, and laboratory tests. Two hundred twenty three patients were studied 
(Table 1). One hundred twenty nine were females (57.84%). One hundred thirty one patients 
were born weighting <1,500 g (58.74%). Apgar score at 1 min was ≤3 in 53 patients, other 
clinical data were obtained from hospital records. 
We detected apnea events in 55 patients (24.66%). Comparison of clinic characteristics 
between infants with and without apnea is shown in Table 2, significant differences were 
found with regard to age, weight, and cephalic perimeter at birth, with lower values in the 
group of infants with apnea as expected by previous literature. No statistical differences in 
main risk factors such as: sepsis, intraventricular hemorrhage, hyperbilirubinemia, hypoxic-
ischemic encephalopathy, meningitis and TORCH in infants with and without apnea were 
seen. Although each patient can have more than one type of apnea, forty patients showed 
central apnea events (72.72%), six manifested obstructive events (10.90%), and nineteen 
demonstrated mixed events (34.54%). Some infants presented only one type of apnea: 
central (n = 31), obstructive (n = 5) and mixed (n = 10). Comparison of characteristics among 
these groups showed significant differences in weight at birth, cephalic perimeter, and one-
min Apgar score with lower values in infants with central and obstructive apnea than 
infants with mixed apnea (Table 3). Significant differences in weight at birth between central 
and mixed groups with regard to infants with obstructive events; and in cephalic perimeter 
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among group of mixed apnea to the other two groups; and in Apgar score at one min in 
groups of obstructive and mixed apnea to group of infants with central events were 
observed. Frequency of three main risk factors identified in patients with only one type of 
apnea showed significant differences when compared with infants without apnea in 
birthweight <1,500 g in the group of infants with central apnea; and in hyperbilirubinemia 
and gastroesophagic reflux in infants with obstructive apnea; and in hyperbilirubinemia and 
sepsis in infants with mixed events of apnea (Table 4). The main pharmacologic agents used 
for apnea treatment were theophylline (n = 21, 38.18%) and aminophylline (n = 14, 25.45%), 
nonetheless twenty patients (36.36%) were without treatment at time of study because they 
were not identified as having apnea events previously.13  
 
n = number of patients. Each subject can have more than one risk factor 
Table 1. Neonatal risk factors in the sample (n = 223 patients) 
 
x = mean. sd = standard deviation. p = probability. n.s. = no significant. CP = Cephalic perimeter 
Table 2. Comparison of characteristics of infants with (n = 55) and without apnea (n = 168) 
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x = mean. sd = standard deviation. p = probability. n.s. = no significant. CP = Cephalic perimeter 
Table 3. Comparison of characteristic of infants with different type of apnea 
 
HB = Hyperbilirubinemia. HM = Hyaline membrane. GR = Gastroesophagic reflux.  
HNa = Hyponatremia. IH = Intraventricular hemorrhage. BD = Bronchopulmonar dysplasia.  
PFC = Persistent Fetal Circulation  FGR = Fetal growth retard. * (p < 0.001) 
Table 4. Main risk factors found in infants with different type of apnea 
6. Pathophysiology 
Several mechanisms have been proposed to explain apnea pathophysiology, such as: 
immaturity of respiratory control center at brainstem, CO2 lower ventilation response at 
REM sleep, lower number of synapsis and myelination at respiratory control center.10,14  
7. Diagnosis and treatment  
The diagnosis is clinical, and is established in basis of a high degree of suspicion of apnea in 
premature high-risk infants. However, some immature at-term infants may also present 
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apnea. Breathing observation and respiratory pauses identification are the cornerstone signs 
for the diagnosis. However, infants with obstructive and mixed apnea may present some 
difficulties for the diagnosis. The PSG is the gold standard study for apnea diagnosis of any 
type because can identify objectively and measure central obstructive and mixed respiratory 
pauses than can be forgetting by visual observation. Thus, every infants with risk factors or 
suspicion for apnea must be send to PSG study. Clinical examination must underline in 
cardio-respiratory and neurological tests. Laboratory studies may include as follows: blood 
test and culture; lumbar puncture; glycemia and calcium measurements; oxygen and carbon 
dioxide levels determination; chest, abdominal and gastro-esophagic serial X-ray; 
echocardiogram; ultrasonography of the brain, and continuous O2 determination.15  
For treatment there are several useful interventions: pharmacological and no-
pharmacological. We will comment one by one as follows. Methylxanthines increase 
chemoreceptor sensitivity as well as respiratory drive and can also improve diaphragmatic 
function. Of the substances available, caffeine has a wider therapeutic range and fewer side 
effects than theophylline. There were concerns, however, that caffeine, being an adenosine 
antagonist, could reduce tolerance to hypoxia and might thus be harmful to infants with 
recurrent hypoxia.16  
Aminophylline will be given at loading dose of 6-8 mg/Kg and a maintenance dose of 1-3 
mg/Kg/dose three times daily to produce a desired plasmatic concentration of 5-12 µg/ml. 
Theophylline will be given at a loading dose of 7.5 mg/Kg and a maintenance dose of 3 
mg/Kg three times daily to produce plasmatic concentrations of 13-20 µg/ml. Caffeine 
could be administered at a loading dose of 25 mg/Kg caffeine citrate and at a maintenance 
dose of 6 mg/Kg to produce plasmatic concentrations of 13-20 µg/ml.17 
Six trials reported on the effect of methylxanthine in the treatment of apnea (three trials of 
theophylline and three trials of caffeine). Five trials that enrolled a total of 192 preterm infants 
with apnea evaluated short term outcomes; in these studies, methylxanthine therapy led to a 
reduction in apnea and use of mechanical ventilation in the first two to seven days. The post-
hoc analysis of the large Central Apnea of Premature Trial comparing caffeine to control in a 
subgroup of infants being treated for apnea reported significantly reduced rates of Persistence 
of Ductus Arterial ligation. Moreover, postmenstrual age at last oxygen treatment, last 
endotracheal tube use, last positive pressure ventilation; and reduced chronic lung disease at 
36 weeks were significantly associated. Methylxanthine was effective in reducing the number 
of apnea attacks and the use of mechanical ventilation in the two to seven days after starting 
treatment. Caffeine is also associated with better longer term outcomes.18  
Other substance used to treat apnea is Doxapram. Doxapram stimulates peripheral 
chemoreceptors at low, and the central at high doses. It shows a clear dose–response curve, 
with a 50% reduction in apnea rate occurring in 47, 65, 82 and 89% of infants at a dose of 0.5, 
1.5, 2.0 and 2.5 mg⁄ kg ⁄ h respectively. Most studies used a continuous intravenous infusion, 
although some suggest that the i.v. solution may also be given orally at twice the dose with 
good effect (enteral absorption is approximately 50%). Short-term side effects become quite 
common at doses above 1.5 mg⁄ kg ⁄ h and include irritability, myoclonus, elevated blood 
pressure and gastric alterations.19 
In the other hand, Continuous-positive airway pressure (C-PAP) has been shown to reduce 
extubation failure in preterm infants, despite the fact that most systems currently available 
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do not reduce work of breathing. C-PAP can be applied via a nasopharyngeal tube or (bi-) 
nasal prongs. Reintubation rates are 40% lower with the latter device, number needed to 
treat, which is why this should be the preferred mode when applying C-PAP. An extension 
to this is Nasal-Intermittent positive pressure ventilation (N-IPPV), which has a high 
effectiveness over C-PAP in preventing extubation failure. Typically, an inspiratory pressure 
of 15–20 cm H2O, applied at a rate of 10–20 ⁄ min., is combined with a C-PAP level of 5–6 cm 
H2O.20 
Other interventions has been studied such as prone head-elevated positioning, keeping 
environmental temperature at the lower end of the thermoneutral range, oscillating 
waterbed and tactile and olfactory stimulation, oxygen administration, increase inspiratory 
CO2 concentration, red blood cell transfusions, and branched-chain amino acid 
supplementation.16 However, these techniques are under study and deserve more 
investigation before be accepted. 
8. References 
[1] Shor Pinsker V, Ugartechea JC, Morales Caballero F, Guzmán Jasso I, López García R, 
Karchmer S. Characterization of fetal functional states Ginecol Obstet Mex. 
1985;53:75-80. 
[2] Poblano A, Haro R, Arteaga C. Neurophysiologic measurement of continuity in the sleep 
of fetuses during the last week of pregnancy and in newborns. Int J Biol Sci. 
2007;4:23-8.  
[3] Hoppenbrouwers T. Polysomnography in newborns and young infants: sleep 
architecture. J Clin Neurophysiol. 1992;9:32-47. 
[4] Scher MS. Ontogeny of EEG sleep from neonatal through infancy periods. Handb Clin 
Neurol. 2011;98:111-29. 
[5] Poblano A, Garza-Morales S. Usefulness of electroencephalography in evaluation of the 
newborn. Bol Med Hosp Infant Mex. 1996;53:144-53. 
[6] Scher MS, Loparo KA. Neonatal EEG/sleep state analyses: a complex phenotype of 
developmental neural plasticity. Dev Neurosci. 2009;31:259-75.  
[7] Darnall RA, Ariagno RL, Kinney HC. The late preterm infant and the control of 
breathing, sleep, and brainstem development: a review. Clin Perinatol. 2006;33:883-
914. 
[8] Curzi-Dascalova L, Christova-Guéorguiéva L, Lebrun F, Firtion G. Respiratory pauses in 
very low risk prematurely born infants reaching normal term. A comparison to 
full-term newborns. Neuropediatrics. 1984;15:13-7. 
[9] Minowa H, Uchida Y, Ebisu R, Yoshibayashi M, Takahashi Y, Yoshioka A. New 
desaturation index to evaluate neonatal apnea using polygraphy. Pediatr Int. 
2003;45:294-300. 
[10] Poets CF. Sleep Med. Apnea of prematurity: What can observational studies tell us 
about pathophysiology? 2010;11:701-7.   
[11] Task Force on Prolonged Apnea. Prolonged apnea. Pediatrics 1978;61:651-2. 
[12] Baird TM. Clinical correlates, natural history and outcome of neonatal apnoea. Semin 
Neonatol 2004;9:205-11. 
[13] Poblano A, Marquez A, Hernandez G. Apnea in infants. Indian J Pediatr. 2006;73:1085-
8. 
 
Neonatal Care 
 
122 
[14] Sale SM. Neonatal apnoea. Best Pract Res Clin Anaesthesiol. 2010;24:323-36. 
[15] Paul K, Melichar J, Miletín J, Dittrichová J. Differential diagnosis of apneas in preterm 
infants. Eur J Pediatr. 2009;168:195-201. 
[16] Poets CF. Interventions for apnoea of prematurity: a personal view. Acta Paediatr. 
2010;99:172-7. 
[17] Scanlon JEM, Chin KC, Morgan MEI, Durbin GM, Hale KA, Brown SS. Caffeine of 
theophylline for neonatal apnea? Arch Dis Child 1992;67:425-8. 
[18] Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm 
infants. Cochrane Database Syst Rev. 2010;12:CD000140. 
[19] Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev. 
2006;12:236-49. 
[20] Campbell DM, Shah PS, Shah V, Kelly EN. Nasal continuous positive airway pressure 
from high flow cannula versus infant flow for preterm infants. J Perinatol. 
2006;26:546-9. 
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
